Article Text

other Versions

PDF
Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty Project
  1. Allan J Wailoo (a.j.wailoo{at}sheffield.ac.uk)
  1. University of Sheffield, United Kingdom
    1. Steve Goodacre (s.goodacre{at}sheffield.ac.uk)
    1. University of Sheffield, United Kingdom
      1. Fiona Sampson (f.c.sampson{at}sheffield.ac.uk)
      1. ScHARR, United Kingdom
        1. Monica Hernandez (monica.hernandez{at}sheffield.ac.uk)
        1. University of Sheffield, United Kingdom
          1. Christian Asseburg (ca{at}ihe.se)
          1. Swedish Institute for Health Economics, Sweden
            1. Stephen John Palmer (sjp21{at}york.ac.uk)
            1. University of York, United Kingdom
              1. Mark Sculpher (mjs23{at}york.ac.uk)
              1. Centre for Health Economics, UK
                1. Keith Abrams (kra1{at}le.ac.uk)
                1. University of Leicester, United Kingdom
                  1. Mark A de Belder (mark.debelder{at}stees.nhs.uk)
                  1. The James Cook University Hospital, Middlesbrough, United Kingdom
                    1. Huon Gray (huon{at}cardiology.co.uk)
                    1. Southampton University Hospital, United Kingdom

                      Abstract

                      Objective: To estimate the cost-effectiveness of primary angioplasty compared to thrombolysis for acute ST-elevation myocardial infarction.

                      Design: Cost analysis of UK observational database, incorporated into decision analytic model.

                      Methods: We compared patients receiving treatment within a comprehensive angioplasty service to control patients receiving thrombolysis-based care. The treatment costs and delays to treatment of thrombolysis and angioplasty were estimated. These estimates were then incorporated into an existing model of cost effectiveness that synthesises evidence from 22 randomised trials to estimate health outcomes in terms of quality-adjusted life years (QALYs).

                      Main outcome measures: Costs from a health service perspective and outcomes measured as quality-adjusted.

                      Results: The mean cost of the initial treatment episode was £3,509 for thrombolysis at control sites, £5,176 for angioplasty in usual working hours at NIAP sites and an additional £245 if undertaken out of hours . Angioplasty-based care had an incremental cost of £4520 per QALY gained and 0.9 probability of being cost-effective at a threshold of £20,000 per QALY gained. This probability was >0.95 if patients were directly admitted to the cardiac catheter laboratory, 0.75 if admitted via the emergency department or coronary care unit, and 0.38 if transferred to the angioplasty centre from another hospital.

                      Conclusions: Overall, primary angioplasty based care is highly likely to be cost-effective at an assumed threshold of £20,000 per QALY gained. It is more likely to be cost-effective if patients are admitted directly to the cardiac catheter laboratory than via other hospital departments, or if transferred from another hospital.

                      Statistics from Altmetric.com

                      Request permissions

                      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.